This Astoria-Pacific SPOTCHECK® Undyttransferase 50-Hour Reagent Kit is for the qualifative determination of galactose-1-phosphate uridyttransferase, EC 2.7.12 (GALT) activity in whole blood saturated filter paper disks (S&S 903 filter paper or equivalent), using the API™ 300 SPOTCHECK® Analyzer or the RFA-300 System. Measurements of galactose-1-phosphate undyttransferase are used in the diagnosis and treatment of the hereditary disease galactosemia. This method is intended for in vitro diagnostic use as an aid in screening for decreased levels of GALT activity in infants. This method is not for monitoring purposes.

Device Description

The proposed device, Unidyttransferase 50-Hour Reagent Kit, is a set of reagents to be used with the API™ 300 SPOTCHECK® Analyzer or the RFA-300 System for the quantitative determination of the enzyme galactose-1-phosphate uridyttransferase (UT) in whole blood saturated filter paper disks. The amount of unidyltransferase activity is determined by measuring the fluorescent compound produced in the reaction of UT with galactose and UDP Glucose, followed by NADP reduction at 37°C. The excitation wavelength of the reaction product is 450 nm, and it's emission is measured at 550 nm. The method is specific for uridy transferase.

The method is designed for mass screening, with enough reagents in each 50-Hour Reagent Kit for 1 week plus start-up (50 hours total) of run time. It is packaged to reduce space and to require a minimum of time to prepare. Each component is packaged with the correct weight to prepare the required volume of reagent. The standard is in a concentrated form, to permit easy dikition to prepare a standard curve.

AI/ML Overview

This document describes the Astoria-Pacific Uridyltransferase 50-Hour Reagent Kit, a device for in vitro diagnostic use to screen for decreased levels of GALT activity in infants. The information provided is sparse regarding detailed acceptance criteria and study particulars, particularly from a modern regulatory submission perspective.

Here's an attempt to extract and interpret the requested information based on the provided text:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly state quantitative acceptance criteria (e.g., specific sensitivity, specificity, or accuracy thresholds). Instead, it relies on a qualitative assessment of "correlation" with known samples.

Acceptance Criteria (Implied)	Reported Device Performance
No false positives	0 false positives
No false negatives	0 false negatives
Results correlated well	Results correlated well

2. Sample size used for the test set and the data provenance

Sample Size for Test Set: 27 specimens
- 20 normal neonatal blood samples
- 7 deficient samples from juveniles and adults
Data Provenance: Not specified, but implied to be from a clinical setting, given the use of "normal neonatal blood samples" and "deficient samples from juveniles and adults." It is highly likely to be retrospective given the submission date and the limited details.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

The document does not provide any information regarding the number or qualifications of experts used to establish the ground truth for the test set.

4. Adjudication method for the test set

The document does not describe any adjudication method.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This is not applicable. The device is a reagent kit for assaying enzyme activity, not an AI or imaging diagnostic device requiring human reader interpretation in the context of an MRMC study.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This is not applicable in the typical sense of algorithm-only performance for an AI/CADe device. The device itself is an in vitro diagnostic assay kit. Its performance is measured by its ability to accurately detect GALT activity, which is a "standalone" measurement in its own right, without human interpretation of complex outputs.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

The ground truth for the deficient samples and normal samples would likely have been established by a reference method for GALT deficiency diagnosis or existing clinical records for those individuals. The document does not explicitly state the specific method used for ground truth establishment, but it implies a pre-existing clinical classification ("normal neonatal blood samples" and "deficient samples").

8. The sample size for the training set

The document does not mention a separate training set. The "clinical tests" described appear to be the entirety of the evaluation. For a reagent kit, the development and calibration process would typically involve internal studies, but these are not disclosed as a "training set" in the context of this summary.

9. How the ground truth for the training set was established

Not applicable, as a separate training set is not explicitly mentioned. If the 27 clinical samples were used for both development and "testing" (which is common in older 510(k) submissions but not ideal by current standards), then the ground truth would have been established as described in point 7.

Summary

{0}------------------------------------------------

K90277

510(k) SUMMARY

Astoria-Pacific

UridyItransferase 50-Hour Reagent Kit

510(K) SUMMARY

IDENTIFICATION

Submitter's Name:

Address:

Telephone: FAX: Contact Person: Date Summary Prepared:

Raymond L. Pavitt, President Astoria-Pacific, Inc. 14600 SE 82nd Drive Clackamas, OR 97015-0830, USA 503-657-3010 503-655-7367 Lester B. Garrison, Diagnostics Manager August 4. 1997

NAME OF DEVICE

Proprietary Name: Common Name: Classification Name: Uridyttransferase (GALT) 50-Hour Reagent Kit Uridyltransferase (GALT) Test System 862.1315 Galactose-1-Phosphate UridyItransferase Test System

LEGALLY MARKETED DEVICE EQUIVALENT TO PROPOSED DEVICE

The Unided and 50-Hour Reagent Kit is substantially equivalent to a legally marketed predicate device, Sigma Galactose-1-Phosphate Uridyttransferase (Gal-PUT) Deficiency Screen.

DESCRIPTION OF PROPOSED DEVICE

DEC | | 1997

{1}------------------------------------------------

510(k) SUMMARY

Astoria-Pacific

Uridy|transferase 50-Hour Reagent Kit

REAGENTS

DESCRIPTION	Component	Concentration	Quantity
GALT Extraction Buffer	Succinate BufferpH 5.2	0.8 mM	1 Liter
Recipient Diluent	Tris Buffer, pH 7.8Triton X-100	100 mM0.5 mL/L	1 Liter
GALT Buffer Part A.	Tris Buffer, pH 7.8NADPDithiothreitol	100 mM1.3 mM1.0 mM	5 x 150 mL
GALT Buffer Part B.	MagnesiumEDTATriton X-100	0.6 mM0.1 mM0.5 mL/L
PGluM Substrate Reagent	Glu-1-Phosphate	10. mM	10 mL
GALT Substrate Reagent	Gal-1-PhosphateUDPGG6PDH YeastPGluM Rabbit Muscle	4.3 mM0.5 mM1.6 KU/L0.8 KU/L	5 x 60 mL
NADH Stock Standard	TEA Buffer, pH 9.0NADH	50 mM50 [Mu]M	2 x 50 mL

INTENDED USE

SUMMARY OF TECHNOLOGICAL CHARACTERISTICS OF DEVICE COMPARED TO PREDICATE DEVICE

Similarities with Predicate Device

The Astoria-Pacific SPOTCHECK® Uricyttransferase 50-Hour Reagent Kit is similar to a predicate device, Sigma Galactose-1-Phosphate Unidythransferase (Gal-PUT) Deficiency Screen, having the same technological characteristics and intended use. Both are diagnostic reagent kits to be used for the qualitative, fluorometric determination of the enzyme uridy/transferase in blood; both have the same chemical principles and reaction mechanism.

{2}------------------------------------------------

510(k) SUMMARY

Astoria-Pacific

UridyItransferase 50-Hour Reagent Kit

The reactants and reactions are the same. Both devices use the same incubation temperature and a similar incubation time.

Differences from Predicate Device

While the method and reagents are similar for the proposed and predicate devices, there are minor differences. The Sigma device uses G6PD and PGluM from the sample for the reactions. The proposed device adds these enzymes to the reagent. The Sigma device requires manual reading of fluorescence; the API™ 300 SPOTCHECK® Analyzer reads the fluorescence automatically.

There are also differences in the wavelengths of the excitation and emission fitters. The proposed device designates 450 nm and 550 nm for the excitation and emission wavelengths, respectively; the Sigma device uses a broad band UV lamp for excitation and visual fluorometry for reading the emitted fluorescence. Because there is a broad bandpass of about 40 nm for the fitters on the APM 300 SPOTCHECK® Analyzer and the emitted fluorescent light is broad spectrum, this difference is not consequential.

The API Uridy/transferase 50-Hour Reagent Kit contains a NADH standard for comparision of the fluorescence readings.

The Sigma Gal-PUT Deliciency Screen test requires the user to prepare all reagents; in the Astoria-Pacific SPOTCHECK® Uridytransferase 50-Hour Reagents are either pre-made or pre-weighed.

The minor differences between the Asloria-Pacific SPOTCHECK® Uridyttransferase 50-Hour Reagent Kit and the Sigma Gal-PUT Deficiency Screen raise no questions of safety or efficacy.

BRIEF DISCUSSION OF NONCLINICAL TESTS

Because there is such a strong similarity between the Astoria-Pacific SPOTCHECK® Uridyttransferase 50-Hour Reagent Kit and the Sigma Gal-PUT Deficiency Screen, no nonclinical testing has been performed to demonstrate substantial equivalence.

BRIEF DISCUSSION OF CLINICAL TESTS

Clinical testing was performed on whole blood saturated fitter paper disks. These tests include 27 specimens analyzed, of which 20 were normal neonatal blood samples and 7 were deficient samples from juveniles and adults. Results correlated well, as there were no false positives and no false negatives among any of the samples tested.

CONCLUSIONS DRAWN FROM THE NONCLINICAL AND CLINICAL TESTS

The clinical tests demonstrate that the proposed device. the Astoria-Pacific SPOTCHECK® Undyttransferase 50-Hour Reagent Kit, is sate, effective and performs as well as a predicate device, as evidenced by the correlation of results obtained from clinical studies.

OTHER INFORMATION

No other information has been requested by FDA at this time.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with flowing lines beneath them.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

DEC I I 1997

Lester B. Garrison Submission Correspondent Astoria-Pacific, Inc. 14600 S.E. 82nd Drive P.O. Box 830 Clackamas, Oregon 97015

K970277 Re : Uridyltransferase Test System Regulatory Class: II Product Code: KQP Dated: November 5, 1997 Received: November 6, 1997

Dear Mr. Garrison:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, qood manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{4}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labelinq regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,
Steven Bitman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Page _ of _

Labels	Values
510(k) Number (if known):	K970277
Device Name:	Undy TRANSFERASE 50-HOUR REAGENT Kit
Indications For Use:

october 8, 1997

Astoria-Pacific, Inc.

statement of Indications for use:

This Astoria-Pacific SPOTCHECK® UridyItransferase 50-Hour Reagent Kit is for the qualitative determination of galactose-1phosphate uridyItransferase (EC 2.7.7.12) (GALT) activity in whole blood saturated filter paper disks, S&S 903 filter paper or equivalent, using the API ™ 300 SPOTCHECK® Analyzer or the RFA-300 System. Measurements of galactose-1-phosphate uridy!transferase are used in the diagnosis and treatment of the hereditary disease galactosemia. This method is intended for In vitro diagnostic use as an aid in screening for decreased levels of GALT enzyme activity in infants. This method is not for monitoring purposes.

(Please Do Not WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

	(Division Sign-Off)
	Division of Clinical Laboratory Devices
510(k) Number	K96277
	OR
Prescription Use	Over-The-Counter Use
(Per 21 CFR 801.109)	(Optional Format 1-2-96)

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number

TOTAL P.08

Regulation Number and Section

§ 862.1315 Galactose-1-phosphate uridyl transferase test system.

(a)
Identification. A galactose-1-phosphate uridyl transferase test system is a device intended to measure the activity of the enzyme galactose-1-phosphate uridyl transferase in erythrocytes (red blood cells). Measurements of galactose-1-phosphate uridyl transferase are used in the diagnosis and treatment of the hereditary disease galactosemia (disorder of galactose metabolism) in infants.(b)
Classification. Class II.